Filter Results
Clinical Studies
Results filtered:Study status:
Open
Contact Us for the Latest Status
Closed for Enrollment
Open
-
A Phase 1/2, Open-Label, Dose-Escalation And -Expansion Study Of The Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 In Patients With B-Cell Malignancies
Jacksonville, FL
Rochester, MN
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
-
A Phase 1b Trial Of Teclistamab In Combination With Iberdomide For Relapsed/Refractory Multiple Myeloma
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating hard-to-treat multiple myeloma. Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to survive. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as teclistamab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving iberdomide in combination with teclistamab may be safe and tolerable in treating patients with multiple myeloma.
-
A Phase 3, Open-Label, Randomized Study To Evaluate The Safety And Efficacy Of BGB-16673 Compared To Pirtobrutinib In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia Or Small Lymphocytic Lymphoma
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).
-
Phase II Trial For Evaluation Of Alternate Doses And Dosing Schedules Of Belantamab Mafodotin In Triple-Class Refractory Multiple Myeloma
Jacksonville, FL
The purpose of this study is to assess the 24-week grade 3/4 keratopathy-free rate of an alternative dose/dosing schedule for belantamab mafodotin in patients with Relapsed/Refractory Multiple Myeloma (RRMM).
-
Randomized Phase 2 Study Comparing Acalabrutinib To Acalabrutinib And Obinutuzumab In The Treatment Of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are At High Risk Of Disease Progression
Jacksonville, FL
Rochester, MN
This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.
Contact Us for the Latest Status
Closed for Enrollment
-
A Phase 1/2, Open-Label, Dose-Escalation And -Expansion Study Of The Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 In Patients With B-Cell Malignancies
Scottsdale/Phoenix, AZ
Study consists of two main parts to explore BGB-16673 recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
-
A Phase 1b, Multicenter, Open-Label, Study To Investigate The Safety And Efficacy Of CLN-619 (Anti-MICA/MICB Antibody) In Patients With Relapsed And Refractory Multiple Myeloma
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to investigate the Safety and Efficacy of CLN-619 (anti-MICA/MICB Antibody) in Patients with Relapsed and Refractory Multiple Myeloma.
-
A Phase I Study To Evaluate The Pharmacokinetics And Safety Of Belantamab Mafodotin Monotherapy In Participants With Relapsed Or Refractory Multiple Myeloma Who Have Normal And Varying Degrees Of Impaired Renal Function (DREAMM 12)
Jacksonville, FL
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in participants with Relapsed/Refractory Multiple Myeloma (RRMM) who have had at least 3 lines of prior treatment and have either normal or impaired renal functions.
Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and majority of MM participants either are at risk or already have renal dysfunction at initial diagnosis.
-
Phase II Trial Of Daratumumab Retreatment In Patients With Relapsed Multiple Myeloma
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The primary goal of this study is to determine the impact of standard of care therapies for TCR MM, in a real-world setting, on patient-reported symptoms, functioning, and QoL, measured prospectively using questionnaires. The secondary goal is to asses clinical endopoints associated with standard of care therapies for TCR MM, in a real-world setting during 12 months of observation.
-
Randomized Phase 2 Study Comparing Acalabrutinib To Acalabrutinib And Obinutuzumab In The Treatment Of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are At High Risk Of Disease Progression
Scottsdale/Phoenix, AZ
This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.
-
The TOTOM Trial: Tai Chi To Optimize Transplant Outcomes For Multiple Myeloma
Jacksonville, FL
The current proposal aims to test the feasibility of immune function analysis for Tai Chi Easy (TCE) intervention in multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT) with concurrent exploration of health related quality of life (HRQOL).
.